Summit Therapeutics reports overall‑survival benefit of ivonescimab in advanced biliary tract cancer
Summit Therapeutics announced that its bispecific antibody ivonescimab plus chemotherapy extended median overall survival to 14.9 months versus 12.1 months for durvalumab plus chemotherapy in a Phase III HARMONi‑GI1 trial of advanced biliary tract cancer. The study showed a 25% reduction in death risk (hazard ratio 0.75) and also improved progression‑free survival (8.4 vs 5.8 months, HR 0.61). Objective response and disease‑control rates were 53.8%/91.5% versus 32.5%/77.8% for the comparator. Summit plans a U.S. registration‑enabling Phase II/III study to start in Q4 2026.
Why it matters
Summit said the data will be used to launch a U.S. registration‑enabling trial in Q4 2026, which could lead to regulatory approval and future revenue streams (). The strong efficacy signals may also lift the company’s valuation as investors price in potential commercial success.
Key facts
- 1Median overall survival was 14.9 months for ivonescimab plus chemotherapy. stocktitan.net
- 2Median overall survival was 12.1 months for durvalumab plus chemotherapy. stocktitan.net
- 3Overall‑survival hazard ratio was 0.75, indicating a 25% reduction in death risk. stocktitan.net
- 4Median progression‑free survival was 8.4 months for ivonescimab plus chemotherapy. stocktitan.net
- 5Median progression‑free survival was 5.8 months for durvalumab plus chemotherapy. stocktitan.net
- 6Progression‑free survival hazard ratio was 0.61. stocktitan.net
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.